Barrett’s Esophagus is a condition in which the normal lining of the esophagus changes to a type similar to the intestinal lining, most commonly due to long-term gastroesophageal reflux disease (GERD). This cellular change is called metaplasia and can increase the risk of developing esophageal adenocarcinoma, a serious form of cancer if left untreated.
Early diagnosis and advanced endoscopic therapies can effectively treat Barrett’s Esophagus and prevent disease progression — offering a safe, minimally-invasive alternative to surgery.
Barrett’s Esophagus often shows no symptoms beyond acid reflux, making proactive management crucial.
Regular monitoring and early endoscopic intervention can remove or destroy abnormal tissue before it becomes cancerous.
Advanced techniques like radiofrequency ablation (RFA) and endoscopic mucosal resection (EMR) provide targeted, organ-preserving therapy with excellent outcomes.
Our centre focuses on personalized treatment, combining surveillance, precision endoscopy, and long-term reflux control.
High-definition endoscopy, narrow-band imaging (NBI), and chromoendoscopy are used to precisely detect Barrett’s changes and early dysplasia (precancerous cells).
Biopsy mapping is performed using the Seattle protocol, ensuring accurate diagnosis and staging.
Surveillance schedules are tailored to the patient’s Barrett’s segment length and histology findings.
EMR is a minimally-invasive technique that removes visible or raised abnormal tissue (nodules, plaques) from the esophageal lining.
It allows both diagnostic and therapeutic removal of dysplastic areas while preserving the esophagus.
EMR is performed under sedation using a flexible endoscope — no external incisions or hospital stay required.
RFA uses controlled, uniform heat energy to eradicate abnormal Barrett’s tissue and promote regrowth of healthy esophageal lining.
The Barrx™ system is the most widely used device for this procedure, with over 90% success in eliminating dysplasia and metaplasia.
Typically performed as an outpatient procedure, RFA offers rapid recovery and minimal discomfort.
For patients with recurrent or resistant Barrett’s tissue, cryoablation uses extreme cold to destroy abnormal cells safely and selectively.
In some cases, combined EMR + RFA or hybrid cryo-RFA approaches are recommended for optimal results.
These therapies are highly effective and preserve swallowing function compared to surgical resection.
Since GERD drives the development and recurrence of Barrett’s Esophagus, long-term reflux control is an integral part of therapy.
Depending on individual cases, management may include proton-pump inhibitors (PPIs), lifestyle modifications, or Transoral Incision-less Fundoplication (TIF) for durable reflux correction.
Before: You’ll undergo diagnostic endoscopy, biopsy, and imaging to confirm diagnosis and rule out invasive cancer.
During: Most procedures are performed under sedation, with minimal discomfort and no external incisions.
After: Patients are discharged the same day, follow a soft diet briefly, and return to routine activities within 1–2 days.
Follow-up: Scheduled endoscopic reviews ensure the treated area heals with healthy squamous lining and that no Barrett’s tissue recurs.
Complete eradication of intestinal metaplasia or dysplasia in 80–95% of cases.
Significant reduction in cancer risk when treated early and monitored regularly.
Most patients experience improved reflux control and quality of life.
Expert gastroenterologists with advanced therapeutic endoscopy training.
Access to state-of-the-art endoscopic systems including high-definition imaging and RFA/EMR platforms.
Multidisciplinary team approach involving gastroenterologists, surgeons, and oncologists.
Personalized long-term surveillance and prevention strategies.
Compassionate patient care with detailed education and counselling.
